Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 89

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 89
---
ylococcus aureus (MRSA),       
 vancomycin-resistant Enterococcus faecium (VRE), and cephalosporin-resistant Neisseria gonorrhoeae 
 [3]. This formulation indicated enhanced uptake by phagocytic cells such as macrophages and        
 neutrophils, potentially improving intracellular antibiotic delivery and bactericidal activity     
 [4].                                                                                               |

| - | No cross-resistance: Due                                                                 
 to its unique mechanism, mupirocin does not display cross-resistance with β-lactams,     
 glycopeptides, or other classes of antibiotics, making it valuable in treating resistant 
 strains [2].                                                                             |

| - | Preclinical profile: Nano-Mupirocin                                                            
 formulations appeared to be well tolerated in preclinical studies, with no significant adverse 
 effects reported [3]. However, these are pre-clinical indications that need to confirmed       
 in appropriate clinical studies.                                                               |

| - | WHO Priority Pathogens: The                                                                        
 World Health Organization (WHO) lists MRSA, VRE, and Neisseria gonorrhoeae among its high-priority 
 pathogens due to increasing antimicrobial resistance [5]. Nano-Mupirocin demonstrated activity     
 against these bacteria which supports its potential relevance in global health initiatives.        |

A team of researchers from the National Institute
of Health in collaboration with Prof. Barenholtz’s team have demonstrated proof of concept in a number of preclinical studies performed
on resistant bacteria which causes severe life-threating infections including necrotizing fasciitis, endocarditis, and gonorrhea. A few
in vitro and in vivo studies testing novel LNP mupirocin were supported and conducted in collaboration with the National
Institute of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID). The results were published in the Antimicrobial
Agents and Chemotherapy journal [6] as well as in the Journal of Controlled Release [7].

While the abovementioned attributes have been observed in preclinical
models, there can be no assurance that they will be replicated in clinical studies or translate into meaningful patient outcomes.

References

| 1. | Williams                                                                                                                             
 JD. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrobial Agents and Chemotherapy. 
 1985;27(4):495–498. DOI: 10.1128/aac.27.4.